Literature DB >> 23238926

Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus.

Francesca Buricchi1, Monia Bardelli, Carmine Malzone, Barbara Capecchi, Uwe Nicolay, Elena Fragapane, Flora Castellino, Giuseppe Del Giudice, Grazia Galli, Oretta Finco.   

Abstract

Cross-protection against divergent strains of influenza virus is an objective of various vaccination approaches. B cells cross-neutralizing several influenza A heterosubtypes have been isolated from cultured human memory B cells (MBCs) and plasmablasts early after influenza vaccination or infection. However, a systematic assessment of the frequency of MBCs and plasmablasts in the blood of healthy individuals is lacking. Here, we show that under resting conditions about 45% of human adults never vaccinated nor exposed to avian A/H5N1 influenza have detectable circulating MBCs cross-reacting with H5N1. This proportion rises to 63.3% among subjects with a large pool of MBCs specific for seasonal H1N1 (i.e. frequency ≥1% of total IgG MBCs). Moreover, subjects with high baseline frequencies of H1N1-specific MBCs had an expansion of H5N1-specific MBCs producing H5-neutralizing antibodies already after the first dose of an MF59-adjuvanted H5N1 vaccine. These results suggest that H1N1-specific MBCs contain a subset of cells cross-reacting to H5. We propose that a proportion of human adults have a pool of H5/H1 cross-reactive MBCs that contribute to the rapid rise of the antibody response to divergent influenza strains. This may have implications on vaccination strategies aimed at counteracting future influenza pandemics.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23238926     DOI: 10.1002/eji.201242563

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.

Authors:  Sean A Gray; Margaret Moore; Emily J VandenEkart; Richard P Roque; Richard A Bowen; Neal Van Hoeven; Steven R Wiley; Christopher H Clegg
Journal:  Antiviral Res       Date:  2016-04-21       Impact factor: 5.970

2.  Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.

Authors:  Sinthujan Jegaskanda; Rosemarie D Mason; Sarah F Andrews; Adam K Wheatley; Ruijun Zhang; Glennys V Reynoso; David R Ambrozak; Celia P Santos; Catherine J Luke; Yumiko Matsuoka; Jason M Brenchley; Heather D Hickman; Kawsar R Talaat; Sallie R Permar; Hua-Xin Liao; Jonathan W Yewdell; Richard A Koup; Mario Roederer; Adrian B McDermott; Kanta Subbarao
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

3.  Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.

Authors:  Christoph T Berger; Victor Greiff; Matthias Mehling; Stefanie Fritz; Marc A Meier; Gideon Hoenger; Anna Conen; Mike Recher; Manuel Battegay; Sai T Reddy; Christoph Hess
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Chronic Ethanol Consumption Reduces Existing CD8 T Cell Memory and Is Associated with Lesions in Protection against Secondary Influenza A Virus Infections.

Authors:  Zeb R Zacharias; Kevin L Legge
Journal:  J Immunol       Date:  2019-11-11       Impact factor: 5.422

Review 5.  Populations at risk for severe or complicated Avian Influenza H5N1: a systematic review and meta-analysis.

Authors:  Dominik Mertz; Tae Hyong Kim; Jennie Johnstone; Po-Po Lam; Michelle Science; Stefan P Kuster; Shaza A Fadel; Dat Tran; Eduardo Fernandez; Neera Bhatnagar; Mark Loeb
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.

Authors:  Alex J Mann; Nicolas Noulin; Andrew Catchpole; Koert J Stittelaar; Leon de Waal; Edwin J B Veldhuis Kroeze; Michael Hinchcliffe; Alan Smith; Emanuele Montomoli; Simona Piccirella; Albert D M E Osterhaus; Alastair Knight; John S Oxford; Giulia Lapini; Rebecca Cox; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

Review 7.  AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Authors:  Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

8.  Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies.

Authors:  Irene Sanjuan Nandin; Carol Fong; Cecilia Deantonio; Juan A Torreno-Pina; Simone Pecetta; Paula Maldonado; Francesca Gasparrini; Jose Ordovas-Montanes; Samuel W Kazer; Svend Kjaer; Daryl W Borley; Usha Nair; Julia A Coleman; Daniel Lingwood; Alex K Shalek; Eric Meffre; Pascal Poignard; Dennis R Burton; Facundo D Batista
Journal:  J Exp Med       Date:  2017-08-07       Impact factor: 14.307

9.  H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines.

Authors:  Sook-San Wong; Jennifer DeBeauchamp; Mark Zanin; Yilun Sun; Li Tang; Richard Webby
Journal:  NPJ Vaccines       Date:  2017-06-08       Impact factor: 7.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.